TITLE: Medicare Reform: Providing Prescription Drug Coverage for Seniors

CIS-NO: 2001-H361-31  
SOURCE: Committee on Energy and Commerce. House  
DOC-TYPE: Hearing Retrieve the full text of testimony  
DATE: May 16, 2001  
LENGTH: iii+102 p.  
CONG-SESS: 107-1  
ITEM-NO: 1019-A-01; 1019-B-01  
SUDOC: Y4.C73/8:107-28  
 
GPO-STOCK-NO: 552-070-27253-4.

SUMMARY:
Committee Serial No. 107-28. Hearing before the Subcom on Health to examine proposals to establish an outpatient prescription drug benefit for medicare beneficiaries. Focuses on anticipated costs associated with medicare prescription drug coverage.
 
Supplementary material (p. 98-102) includes a submitted statement.

CONTENT-NOTATION: Medicare prescription drug benefit proposals

DESCRIPTORS:  
   SUBCOM ON HEALTH, ENERGY AND COMMERCE. HOUSE;  MEDICARE; DRUGS; MEDICAL REGULATION; MANAGED HEALTH CARE

01-H361-31 TESTIMONY NO: 1     May 16, 2001 p. 18-65
 
WITNESSES (and witness notations):
   CRIPPEN, DAN L. (Director, CBO)
 
STATEMENT AND DISCUSSION:
   Analysis of costs associated with including prescription drug coverage in medicare benefits (related tables, graphs, p. 31-41); financial issues related to proposed medicare prescription drug benefit.
 
INSERTION:
   -- O'Sullivan, Jennifer and Graves, Bud (CRS), "Health Care Fact Sheet: Original Medicare Cost Estimates" Sept. 22, 1993, with tables (p. 60-61).
 
CONTENT NOTATION:
   Medicare prescription drug benefit proposals
 
TESTIMONY DESCRIPTORS:
   CONGRESSIONAL BUDGET OFFICE; STATISTICAL DATA: HEALTH AND VITAL STATISTICS; STATISTICAL DATA: PUBLIC WELFARE AND SOCIAL SECURITY; CONGRESSIONAL RESEARCH SERVICE
 
 
01-H361-31 TESTIMONY NO: 2     May 16, 2001 p. 65-98
 
WITNESSES (and witness notations):
   BRAUN, BEATRICE S. (Board Member, AARP)
   LAMBREW, JEANNE M. (Associate Professor, George Washington University)
   CHESS, ROBERT (Chairman, Inhale Therapeutic Systems; representing Biotechnology Industry Organization)
 
STATEMENTS AND DISCUSSION:
   Importance of establishing prescription drug benefits, with related policy recommendations (related graphs, p. 71-72); adequacy of various cost estimates associated with prescription drug coverage for medicare beneficiaries (related graphs, p. 80-82).
 
CONTENT NOTATION:
   Medicare prescription drug benefit proposals
 
TESTIMONY DESCRIPTORS:
   AARP; BIOTECHNOLOGY INDUSTRY ORGANIZATION

LOAD-DATE: November 22, 2002